IOVA
Iovance Biotherapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical
Market Cap: 4.79 Billion
Primary Exchange: NASDAQ
Website: iovance.com
Shares Outstanding: 279 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.6066222366518086
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 996 trading days
From: 2021-02-08 To: 2024-03-07
Lowest Point:
Iovance Biotherapeutics Is The Next Biotech Takeover Candidate For Its Breakthrough TILs Technology
via: SeekingAlpha at 2019-06-13 07:00:05:000
I got interested in Iovance Biotherapeutics ( IOVA ) after attending the management presentation at the Jefferies annual immuno-oncology day in Boston a couple of months back. The management presented interesting preliminary data from its tumor infiltrating lymphocytes, TILs in refractory adva… read more...
Iovance Makes Significant Impact At ASCO 2019 Conference With Cancer Drug
via: SeekingAlpha at 2019-06-11 10:52:56:000
Iovance Biotherapeutics ( IOVA ) had made a very large impact at ASCO 2019 and it was one of the clear winners for the medical conference. That's because it reported positive results from two of its studies. The positive results were made possible through the use of the biotech's Tumor infil… read more...
Iovance Makes Significant Impact At ASCO 2019 Conference With Cancer Drug
via: SeekingAlpha at 2019-06-11 10:52:56:000
Iovance Biotherapeutics ( IOVA ) had made a very large impact at ASCO 2019 and it was one of the clear winners for the medical conference. That's because it reported positive results from two of its studies. The positive results were made possible through the use of the biotech's Tumor infil… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|